Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2026
-
Wawrinka falls in first round of Monte Carlo Masters
-
Ex-England rugby international Lawes to leave Brive
-
Fit-again Mbappe at Real Madrid for clashes like Bayern tie: Arbeloa
-
Swimmers McKeown, O'Callaghan and Chalmers dominate at Australian Open
-
Bucha: When the Russian killers came...
-
Iran, a Terrorist State with No Right to Exist
-
African players in Europe: Semenyo scores as City rout Liverpool
-
Israeli strikes kill Iran Guards intel chief as Trump deadline looms
-
Saving energy in everyday life or a complete rip-off?
-
US sprint star Richardson wins Australia's Stawell Gift in record time
-
Rockets down Warriors in Curry return, Flagg carries Mavs past Lakers
-
Artemis mission approaches lunar loop for first flyby since 1972
-
Israeli rescuers search for missing in building strike, two dead
-
Defiant Iran ramps up attacks after Trump warning
-
Saudi oasis town adjusts to life in the firing line
-
Pogacar stays humble with Monument history beckoning
-
Real Madrid hoping Champions League magic halts Bayern juggernaut
-
Sputtering Arsenal face test of character in Sporting clash
-
'Not the Cairo we know': Energy shock from Iran war dims Egypt nights
-
Tokyo, Seoul shares gain, war sends oil higher
-
Artemis mission headed for first lunar flyby since 1972
-
South Korea president says regrets 'reckless' drones sent to North
-
Coughlin captures third LPGA title at Aramco Championship
-
What to know about the Artemis 2 mission's Moon flyby
-
Mystique of the green jacket endures as Masters looms
-
In El Salvador's mass trials, 'the innocent pay for the guilty'
-
Trump makes stark threat to Iran after US airman rescued
-
MyPlanAdvocate Rebrands as MPA and Integrates HealthyLabs, Bringing AI-Powered Performance Marketing In-House
-
XCF Global and Axens North America Announce Commercial Collaboration for Vegan(R) Technology
-
SMX Launches Digital Material Passport Platform (DMPP) Enabling Verified Material Identity, Traceability and Real-World Asset Tokenization
-
TrustNFT Releases White Paper on Corporate Costs of Email Impersonation, Documenting $2.9 Billion in Annual Losses and Growing Brand Liability Risk
-
Commonwealth Wholesale Corporation Signs Lease at Central Port Logistics Center Building 4 Strategically Located Near the Port of Savannah
-
Datavault AI CEO Nathaniel T. Bradley to Deliver Flagship Keynotes on Breakthrough RWA Tokenization at CONV3RGENCE London and AssetRush × Zurich 2026
-
HarrisQuest Launches Lou, a Voice-Enabled AI Analyst Built Inside The Harris Poll's Brand Tracking Platform
-
Fortitude Gold Declares April 2026 Monthly Dividend
-
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
-
Arrive AI Secures Tenth U.S. Patent, Positioning as the Critical Infrastructure Layer for Autonomous Delivery at Scale
-
National Study of 2,300+ Women Finds Social Connection Shapes Volunteer Experience Amid Competing Work, Caregiving, and Life Demands
-
Prof. Abdul Al Lily Announces the Release of The Naughty AI CEO, Exploring the Future of AI-Driven Leadership
-
Hillcrest Closes Shares for Debt Offering
-
Elektros Positions Itself at the Center of High-Stakes EV Infrastructure Opportunity Through Strategic Engagement with Major Global Automotive Leader
-
ReElement Technologies Announces April Conference and Event Schedule
-
Greenpro Capital Corp. Successfully Acquires Stake in AI Forekast Limited, an Augmented Intelligence Provider
-
Ondas' 4M Defense Wins Competitive Tender for Large-Scale Border Demining Program with Opportunity Expected to Exceed $50 Million
-
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
-
MDCE's Snapshot Recipes App Scales Marketing Strategy Beyond Initial Podcast Deals with Expanded iHeart Campaign
-
SMX Announces Launch of Its Digital Material Passport Platform, Enabling Real-World Asset Tokenisation and Global Material Traceability
-
Bora Biologics Successfully Completes 2,000L Engineering and Scale-Up Run in San Diego, Reinforcing Commercial-Scale Readiness
-
Avino Announces Normal Course Issuer Bid for Common Shares
-
Revolve Signs Interconnection Agreement for 130 MW EL 24 Wind Project in Mexico
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2026
DORADO, PUERTO RICO / ACCESS Newswire / March 17, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2026 were approximately $2.3 million, a decrease of approximately $0.2 million when compared to the same period last year. Net income for the quarter ended January 31, 2026 was $32,860, an improvement of $24,324 when compared to the same quarter last year.
"We entered this fiscal year focused on executing the strategic priorities established over the past several quarters-sharpening our service portfolio, reinforcing operational alignment, and concentrating on the markets where our capabilities create the most value. We are encouraged by the progress made in improving operational efficiency, which allowed us to deliver a modest profit compared to a slight loss in the same period last year. As we look ahead, we will continue strengthening client relationships, maintaining disciplined cost management, and aligning our organization with the areas of greatest opportunity. We remain confident that these efforts position us well to build momentum and deliver long term value to our shareholders," said Mr. Sanchez, Chief Executive Officer.
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, and competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2025, and in its other filings with the Securities and Exchange Commission, which filings are available at www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709
SOURCE: Pharma-Bio Serv Inc.
View the original press release on ACCESS Newswire
M.O.Allen--AT